Navigation Links
Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
Date:9/8/2009

DURHAM, N.C., Sept. 8 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that it has formally notified Vatea Fund of the company's achievement of a milestone under the Securities Purchase Agreement dated June 8, 2009, as amended September 1, 2009. The milestone is a Clinical Trial for Oxycyte in Traumatic Brain Injury Approved by Swissmedic.

With the achievement of the milestone, the agreement calls for Vatea Fund to purchase 24 million shares of Oxygen Biotherapeutics stock from the company for $6 million with the transaction to close no later than December 10, 2009.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
2. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Conn. , June 3, 2015  SurgiQuest®, ... innovative access technologies for minimally invasive surgery (MIS) ... AirSeal® System in over 250,000 procedures.  Adoption has ... procedures over last year, driven by the company,s ... as well as geographic expansion to over 45 ...
(Date:6/3/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/rf4hfn/global ) has ... Diseases Market 2015-2019" report to their offering. ... grow at a CAGR of 4.77% over the ... present scenario and the growth prospects of the ... To calculate the market size, the report considers ...
(Date:6/3/2015)... CAMBRIDGE, Mass. , June 3, 2015  EIP ... dosing in phase 2 clinical development of VX-745 in ... brain penetrant, highly selective and potent inhibitor of the ... protein kinase (p38 MAPK alpha). "Recent human ... of disease in patients with symptomatic Alzheimer,s, while the ...
Breaking Medicine Technology:Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... , April 26 Sirion Therapeutics, Inc., a ... ophthalmic gel) 0.15% is now commercially available.  Zirgan™, which was ... September 2009 , is a topical ophthalmic antiviral indicated for ... , , ...
... TARRYTOWN, N.Y. , April 26 Bayer Diabetes ... blood glucose monitoring system in the United States . ... the only blood glucose meter that connects directly to Nintendo ... kids manage a lifelong disease by rewarding them for building ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Bayer Diabetes Care Introduces DIDGET In the US 2Bayer Diabetes Care Introduces DIDGET In the US 3Bayer Diabetes Care Introduces DIDGET In the US 4Bayer Diabetes Care Introduces DIDGET In the US 5
(Date:6/3/2015)... June 03, 2015 Researchers at the ... for mesothelioma and say the tried-and-true marker mesothelin is ... an article on the research. Click here to ... National Center for Asbestos Related Diseases say, even though ... it is still preferable to fibulin-3 for identifying mesothelioma. ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 According to ... police officers intercepted fake oxycodone pills which actually ... were doctored to look legitimate, and even sported the ... are warning those consuming 30 mg oxycodone to be ... pills online or buy them illegally on the street. ...
(Date:6/3/2015)... June 03, 2015 Fourroux Prosthetics, located ... GA will celebrate its grand opening with a ribbon ... first prosthetic center of its kind in the area, ... unmatched care and outcomes through use of patented advanced ... & CEO of Fourroux Prosthetics, states, “Our goal has ...
(Date:6/3/2015)... June 03, 2015 DailyEndorphin is pleased ... programming module. With this highly configurable new offering, ... report on many components of its wellness programming for ... additional charge. , With this new module, annual clients ... challenges, (2) Create participant surveys, (3) Continually report on ...
(Date:6/3/2015)... June 03, 2015 On May 29, ... Authorization (MA), effective immediately, which now permits the use ... contain oats as ingredients. The MA is a prelude ... All stakeholders should be aware that, unlike the unlimited ... USA, there are restrictions for gluten-free oat products sold ...
Breaking Medicine News(10 mins):Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 3
... 21 The Hispanic got milk? Milk Mustache Mobile,Drink Well. ... tour, including,the top 10 Hispanic cities, to reintroduce Hispanics to ... cruised through Denver,hosting free events to encourage local residents to ... drink -- milk. , At the ...
... Challenges for the Summer of 2009NEW YORK, May 21 ... in Manhattan, Long Island, Hudson Valley, Brooklyn / Staten Island, ... to maintain an adequate and safe blood supply for hospital ... Flu) , Some high school blood ...
... Economic Times Bring Experienced Nurses Back To Job MarketBERKELEY, Calif., ... nurses at hospitals -- a result of the economic recession ... Jones, RN, MS, executive director of the California Institute for ... in hospitals, so a slow down in admissions is just ...
... linked to higher stress levels in adolescence , , THURSDAY, May ... time in child-care facilities or who had insensitive mothers may ... long-term study suggests. , The conclusion is based on a ... , that by age 15 these children are more ...
... May 21 St. David,s HealthCare was named the number ... third consecutive year at the Austin Business Journal ,s ... 2009."Being named a ,Best Place to Work, is a tribute ... St. David,s HealthCare; our business is a team effort, and ...
... fewer signs of condition , , THURSDAY, May 21 (HealthDay News) ... has been identified by U.S. researchers, who said their finding ... , The researchers found that mice without the ion channel ... to normal mice, those lacking the gene for TRPA1 had ...
Cached Medicine News:Health News:The Hispanic got milk? Campaign Visited Denver May 17th - May 20th 2Health News:It's Summer; Patients Need Us to Donate Blood! 2Health News:Hard Times for Nursing Hires Doesn't Signal End to Shortage According to California Institute for Nursing & Health Care 2Health News:Teen Stress May Have Roots in First Three Years of Life 2Health News:St. David's HealthCare Named #1 Best Place to Work Among Large Central Texas Employers for Third Consecutive Year 2
... With the GE Innova 2100IQ: See the ... legs. Place interventional devices. Its all enabled ... panel that helps deliver excellent image quality ... Innova family systems installed worldwide, more physicians ...
... provides clinically valuable, device-derived information applicable ... to help specialty physicians discern if ... stable or deteriorating. For example, heart ... Medtronic InSync Sentry™ CRT-D system can ...
... (ALS) is a GH dependent protein which is ... acid peptide with a predicted molecular weight of ... confined to a ~150 KDa GH-dependent ternary protein ... or IGF-II, and this unique acid-labile subunit (ALS) ...
... was first identified in 1980 (1) and has ... of appetite (2). PYY is produced by the ... intake, and is found to decrease appetite. The ... the circulation is PYY3-36, the N-terminal truncated form ...
Medicine Products: